Most patients receiving multimodality cancer care receive care from different practices. Therefore, episode-based payments in oncology must hold multiple providers accountable for costs and quality.
Nancy L. Keating, MD, MPH
Advertisement
Articles by Nancy L. Keating, MD, MPH
Medicare-Advantage Prescription drug plans (MA-PDs) and standalone PDPs appear to respond to different incentives for plan design.
Advertisement
Latest Updated Articles
- Multimodality Cancer Care and Implications for Episode-Based Payments in Cancer
Published: November 12th 2019 | Updated:
- Drug Plan Design Incentives Among Medicare Prescription Drug Plans
Published: July 21st 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices
2
CMS Announces GENEROUS Model to Lower Medicaid Drug Prices
3
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM
4
Adolescents, Young Adults Use AI Chatbots for Mental Health Advice
5
